Literature DB >> 2413929

Prognostic value of estrogen receptors determined by radiochemical vs. histochemical methods in breast cancer.

P Sismondi, V Aimone, F Genta, G Voglino, F Deltetto, G Giardina, G Botta, B Ghiringhello, M P Mano, P Zola.   

Abstract

Estrogen receptors (ER) were evaluated in 634 breast cancer patients by the dextran-coated charcoal method (DCC). In 206, ER and progesterone receptors (PR) were also tested by cytochemistry (Lee method), and in 124 ER were tested by immunofluorescence (Pertschuk method). The median follow-up is 3.7 years. Comparisons have been made between receptor content and: anatomical and clinical features, disease-free survival (DFS), and survival. The following conclusions can be drawn: there is no correlation between ER determinations by DCC and by immunofluorescence or cytochemical methods; there is no evidence of association between ER and PR determined by Lee's method and anatomical and clinical features; a highly significant positive association was found between ER rich specimens and age, post-menopausal status, lobular and tubular histologic types; there is no association between ER values and TNM stage, WHO grading, pathologic prognostic factors of primary tumor and of lymph nodes; and the DFS was not affected by ER status, except for tumors with more than 50 fmol/mg protein.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2413929     DOI: 10.1007/bf01806012

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  25 in total

1.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

2.  Covariance analysis of censored survival data.

Authors:  N Breslow
Journal:  Biometrics       Date:  1974-03       Impact factor: 2.571

3.  Radio-ligand binding assay of specific estrogens using a soluble uterine macromolecule.

Authors:  S G Korenman
Journal:  J Clin Endocrinol Metab       Date:  1968-01       Impact factor: 5.958

4.  Affinity cytochemistry visualizes specific estrogen binding sites on the plasma membrane of breast cancer cells.

Authors:  I Nenci; E Marchetti; A Marzola; G Fabris
Journal:  J Steroid Biochem       Date:  1981-11       Impact factor: 4.292

5.  Hormone receptors and breast cancer.

Authors:  J H Howanitz
Journal:  Hum Pathol       Date:  1981-12       Impact factor: 3.466

6.  Combination chemotherapy as an adjuvant treatment in operable breast cancer.

Authors:  G Bonadonna; E Brusamolino; P Valagussa; A Rossi; L Brugnatelli; C Brambilla; M De Lena; G Tancini; E Bajetta; R Musumeci; U Veronesi
Journal:  N Engl J Med       Date:  1976-02-19       Impact factor: 91.245

7.  The value of estrogen and progesterone receptors in the treatment of breast cancer.

Authors:  C K Osborne; M G Yochmowitz; W A Knight; W L McGuire
Journal:  Cancer       Date:  1980-12-15       Impact factor: 6.860

8.  Oestrogen and progesterone receptor content and the distribution of histological grade in breast cancer.

Authors:  S Thoresen; T Thorsen; M Tangen; F Hartveit
Journal:  Breast Cancer Res Treat       Date:  1982       Impact factor: 4.872

9.  Correlation of estrogen receptors and response to chemotherapy of cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in advanced breast cancer.

Authors:  J C Chang; G Wergowske
Journal:  Cancer       Date:  1981-12-01       Impact factor: 6.860

10.  Estrogen receptors and responsiveness of advanced breast cancer to chemotherapy.

Authors:  B A Samal; S C Brooks; G Cummings; L Franco; E A Hire; S Martino; A Singhakowinta; V K Vaitkevicius
Journal:  Cancer       Date:  1980-12-15       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.